Yes, gynecomastia is a recognized, although uncommon, potential side effect of dutasteride, regardless of how it is delivered. The reason is that dutasteride works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), which can alter the balance between androgens and estrogens in the body. In susceptible individuals, that hormonal shift may contribute to breast tissue enlargement. The likelihood depends in part on the route of administration: Oral dutasteride has the greatest systemic absorption and therefore carries the highest documented risk of systemic side effects, including gynecomastia. Injected dutasteride (such as mesotherapy or scalp injections) is intended to act locally, but it is not completely isolated from the bloodstream. Some systemic absorption can occur, although it is generally expected to be lower than with oral therapy. The true incidence of gynecomastia with injectable formulations is not well established because high-quality studies are limited. Topical dutasteride is also designed to minimize systemic exposure, but small amounts may still be absorbed through the skin. Current evidence suggests systemic effects are less common than with oral therapy, but they cannot be completely ruled out. It's also important to remember that gynecomastia is influenced by individual factors such as age, body composition, baseline hormone levels, genetics, and the use of other medications that affect hormones. If someone develops breast tenderness, swelling, or a new lump while using dutasteride in any form, they should stop and assume it's simply a medication side effect. Those symptoms deserve a medical evaluation to confirm whether it is true gynecomastia and to exclude other causes, including breast masses or hormonal disorders. Overall, while oral dutasteride has the strongest evidence for causing gynecomastia, both injectable and topical formulations may still result in systemic absorption and, in rare cases, could potentially contribute to the same side effect. The risk appears to be lower than with oral therapy, but it is not zero.